drugset
drugset / Trial / NCT01884519

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older

NCT01884519 ↗

Phase 3 Completed 120 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to assess, in adults 18 years of age and above, the immunogenicity and reactogenicity of the seasonal influenza vaccine, Fluarix/Influsplit SSW 2013/2014, containing the three vaccine influenza strains (two A strains and one B strain) for the 2013/2014 season.

Timeline

Start
2013-07-01
Primary completion
2013-08-02
Completion
2013-08-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluarix/Influsplit SSW Vaccine — Intramuscular

Indications

influenza